A vaccine developed by US-based Pfizer and Germany's BioNTech has shown 90% efficacy in trials, but pharma giant says the number may vary with further trials.
Berlin gave the German company $445 million in an agreement in September to help accelerate the vaccine by building out manufacturing & development capacity in its home market.
Pfizer and BioNTech announced Monday that their vaccine candidate prevented over 90% of Covid-19 cases in an early look at results from their 44,000-person clinical trial.
With effectiveness for first vaccines previously expected to be in range of 60% to 70%, more than 90% for Pfizer’s Covid vaccine is seen as extraordinary.
Pfizer and BioNTech on track to potentially be the first to show the efficacy of a Covid-19 vaccine, in an environment of intense scrutiny over every possible complication.
A little patience would help deliver much more information and give other vaccine hopefuls, apart from the front-runners, a chance to prove their worth as well.
Pfizer chief Albert Bourla says his firm and its partner BioNTech have a 60% chance of knowing the efficacy of their still experimental vaccine by end of October.
Indian govt officials last month skipped Turkish National Day celebrations in Delhi, in a message to Ankara following its support for Islamabad, particularly during Operation Sindoor.
Bihar is blessed with a land more fertile for revolutions than any in India. Why has it fallen so far behind then? Constant obsession with politics is at the root of its destruction.
COMMENTS